InnoSkel
Latest round
- Series A
Last raised
- Jan 2021
Total raised
- $24M
Investors
- 4
About InnoSkel
InnoSkel is engaged in biotechnology, specifically targeting type 2 collagenopathies with its main program.InnoSkel is focused on developing innovative therapies aimed at treating type 2 collagenopathies. Upcoming initiatives include the selection of a lead drug candidate targeted for type 2 collagenopathies and the recruitment of a Chief Medical Officer. Additionally, the company aims to transition its laboratory operations from Inserm to its own premises and ensure full dedication from its CEO, Elvire Gouze, to the firm. These steps are expected to enhance InnoSkel's operational capabilities and advance its growth trajectory in the biotechnology sector.
Who invested in InnoSkel
4 investors across 1 round
See all investors in InnoSkel
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 20, 2021
Amount
$24M
Investors
Questions about InnoSkel
Who invested in InnoSkel?
InnoSkel has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has InnoSkel raised?
InnoSkel has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did InnoSkel last raise money?
InnoSkel's most recent round on record is a Series A, in Jan 2021.
What does InnoSkel do?
InnoSkel is engaged in biotechnology, specifically targeting type 2 collagenopathies with its main program.
Where is InnoSkel headquartered?
InnoSkel is headquartered in France.
Which VCs invest in companies like InnoSkel?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at InnoSkel's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like InnoSkel? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.